The Swiss psychiatrist Carl Gustav Jung wrote : "He who has achieved a perception of reality is inevitably solitary" [This is a translation of the Russian version of Jung's essay "The Spiritual Problem of Modern Man". The standard English version reads somewhat differently: "The man whom we can with justice call 'modern' is solitary"--Trans.].  

Если Вы хотите прочитать оригинал данной статьи на русском языке, нажмите сюда.

I first read these lines sitting in jail as a political prisoner of the Russian state.  In the gulag reality is somehow quickly perceived, literally with the skin. And also - by the state of health. I did not meet people who after jail would remain healthy for

...

A panel of experts of the US Food and Drug Administration (FDA) has recently asked for additional data to judge the efficacy of Human Genome Sciences Inc.’s (HGSI) anthrax infection treatment ABthrax (raxibacumab) compared to existing anti-bacterial drugs.  The panel of experts voted 17 to 6, with one abstention, that the company should submit more evidence on whether adding ABthrax to older drugs is beneficial for anthrax treatment.  Data from studies had revealed that antibiotic medicines used alone were highly effective against anthrax, thereby raising questions about the added benefit of ABthrax. Furthermore, the drug appeared to be effective when used with antibiotics in rabbits and monkeys. The same panel also voted in favor of using data from the animal studies to predict how the drug will work in humans. However, more data is required for the purpose. Last week, the FDA expressed concerns regarding some ...

Recently, Human Genome Sciences Inc. (HGSI) suffered a setback when the US Food and Drug Administration (FDA) questioned the efficacy of its drug ABthrax (raxibacumab), meant for treating anthrax infection.  The FDA accepted that the medication was more effective than a placebo in treating anthrax exposure in animals. However, it was unsure as to how effective the treatment would be for humans since the reliability of human data is doubtful. Though the drug appeared to be effective when used with antibiotics in rabbits and monkeys, animal studies do not always predict success in humans.  Later today, an advisory panel from the FDA is scheduled to meet to decide whether the benefits of the drug outweigh the risks for treating deadly infections caused by anthrax inhalation.  As a reminder, Human Genome had filed a Biologics License Application with the FDA in May 2009. The company is ...

Today, Novartis (NVS) acquired exclusive worldwide rights to PTK 0796, a broad spectrum antibiotic from a privately held company, Paratek Pharmaceuticals. The drug is meant for the treatment of infections caused by drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumoniae (MDRSP). PTK 0796, being a broad spectrum antibiotic, could be used as a single agent against a range of bacteria unlike other antibiotics, which may have to be used in combination. Although we are yet to know the exact financial terms of the deal, Novartis will be making an upfront payment to Paratek in addition to future milestone payments and royalties. Both the companies will share the costs and responsibilities related to the drug’s development. A phase III trial for the drug is being conducted for the treatment of complicated skin and skin structure infections (cSSSI). Clinical studies conducted on more ...

Companies often stumble in certain areas only to come back stronger and more profitable as issues are addressed and overcome. In certain areas, this particular type of problem is more easily overcome then in others, especially when the profit potential is exceedingly large. The generic drug market is one such area and one that will be extremely profitable in coming years.

Caraco Pharmaceutical Laboratories Inc., a generic drug manufacturer, works to provide generic drugs to a host of mass merchant pharmacy outlets, warehouses, wholesalers and distributors. The company offers a wide array of generic prescription drugs targeted at main stream diseases.

Although the pharma sector has been finding solid successes of late and banked solid capital reserves, there is certain trepidation with regard to product going “off-patent” in the relative near-term. There are many new products to fill this “off-patent” issue, but many products that will leave the patent scenario have

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday September 28, 2009

DrStockPick.com Stock Report!

PWRM, SHMN, MRK, TSPG, AQNM

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete

...

DrStockPick.com Stock Report!

Monday September 14, 2009

**************************************************************

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the presentation of results from its second prulifloxacin Phase 3 clinical study for the treatment of infectious diarrhea in travelers, by clinical investigator Robert Steffen, M.D., at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

...

Today the Census Bureau released its report on incomes, poverty and health insurance coverage for 2008. Most of it was (not surprisingly) bad news. Here are some of the highlights (lowlights?): The U.S. Census Bureau announced today that real median household income in the United States fell 3.6 percent between 2007 and 2008, from $52,163 to $50,303. The nation’s official poverty rate in 2008 was 13.2 percent, up from 12.5 percent in 2007. There were 39.8 million people in poverty in 2008, up from 37.3 million in 2007. The number of people without health insurance coverage rose from 45.7 million in 2007 to 46.3 million in 2008, In 2008, the earnings of women who worked full time, year-round was 77 percent of that for corresponding men, not statistically different from the 2007 ratio. The ...

Last week, Cornerstone Therapeutics Inc. (CRTX) announced the receipt of approval from the United States Bankruptcy Court for Massachusetts district regarding the acquisition of Factive's (gemifloxacin mesylate) commercial rights  in North America and some European countries from Oscient Pharmaceuticals Corp., which filed for Chapter 11 bankruptcy protection in July. The transaction is worth $5 million in cash. Additionally, it includes an amount for purchased inventory, quarterly royalty payments based on adjusted net sales for a period of five years, and the assumption of certain liabilities. Factive, which belongs to the fluoroquinolone class of antibiotics, is indicated for the treatment of community-acquired pneumonia (CAP) of mild to moderate severity and acute bacterial exacerbations of chronic bronchitis (ABECB).  It was launched in the U.S. in September 2004 and is the only fluoroquinolone approved in the U.S. for the five-day treatment of both ABECB and CAP. Factive has generated ...

Cornerstone Therapeutics Inc (CRTX), a North Carolina-based specialty pharma company, got into a definitive asset purchase agreement with biopharmaceutical company Oscient Pharmaceuticals Corp. (OSCI) on July13, 2009. Under the agreement, CRTX agreed to purchase the commercial rights of Factive (gemifloxacin mesylate) for $5 million in North America and some European countries from OSCI, which has filed for Chapter 11 bankruptcy protection. Subsequently, the bankruptcy court is expected to pass its verdict within the next two months. Factive is indicated for the treatment of community-acquired pneumonia (CAP) of mild to moderate severity and acute bacterial exacerbations of chronic bronchitis (AECB).  Factive belongs to the fluoroquinolone class of antibiotics. It received FDA approval in May 2007 for the five-day treatment of CAP. Cornerstone Therapeutics currently promotes its products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. Cornerstone also ...